RT Journal Article
SR Electronic
T1 Delayed rise of oral fluid antibodies, elevated BMI, and absence of early fever correlate with longer time to SARS-CoV-2 RNA clearance in an longitudinally sampled cohort of COVID-19 outpatients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.02.21252420
DO 10.1101/2021.03.02.21252420
A1 Antar, Annukka A. R.
A1 Yu, Tong
A1 Pisanic, Nora
A1 Azamfirei, Razvan
A1 Tornheim, Jeffrey A.
A1 Brown, Diane M.
A1 Kruczynski, Kate
A1 Hardick, Justin P.
A1 Sewell, Thelio
A1 Jang, Minyoung
A1 Church, Taylor
A1 Walch, Samantha N.
A1 Reuland, Carolyn
A1 Bachu, Vismaya S.
A1 Littlefield, Kirsten
A1 Park, Han-Sol
A1 Ursin, Rebecca L.
A1 Ganesan, Abhinaya
A1 Kusemiju, Oyinkansola
A1 Barnaba, Brittany
A1 Charles, Curtisha
A1 Prizzi, Michelle
A1 Johnstone, Jaylynn R.
A1 Payton, Christine
A1 Dai, Weiwei
A1 Fuchs, Joelle
A1 Massaccesi, Guido
A1 Armstrong, Derek T.
A1 Townsend, Jennifer L.
A1 Keller, Sara C.
A1 Demko, Zoe O
A1 Hu, Chen
A1 Wang, Mei-Cheng
A1 Sauer, Lauren M.
A1 Mostafa, Heba H.
A1 Keruly, Jeanne C.
A1 Mehta, Shruti H.
A1 Klein, Sabra L.
A1 Cox, Andrea L.
A1 Pekosz, Andrew
A1 Heaney, Christopher D.
A1 Thomas, David L.
A1 Blair, Paul W.
A1 Manabe, Yukari C.
YR 2021
UL http://medrxiv.org/content/early/2021/03/03/2021.03.02.21252420.abstract
AB Background Sustained molecular detection of SARS-CoV-2 RNA in the upper respiratory tract (URT) in mild to moderate COVID-19 is common. We sought to identify host and immune determinants of prolonged SARS-CoV-2 RNA detection.Methods Ninety-five outpatients self-collected mid-turbinate nasal, oropharyngeal (OP), and gingival crevicular fluid (oral fluid) samples at home and in a research clinic a median of 6 times over 1-3 months. Samples were tested for viral RNA, virus culture, and SARS-CoV-2 and other human coronavirus antibodies, and associations were estimated using Cox proportional hazards models.Results Viral RNA clearance, as measured by SARS-CoV-2 RT-PCR, in 507 URT samples occurred a median (IQR) 33.5 (17-63.5) days post-symptom onset. Sixteen nasal-OP samples collected 2-11 days post-symptom onset were virus culture positive out of 183 RT-PCR positive samples tested. All participants but one with positive virus culture were negative for concomitant oral fluid anti-SARS-CoV-2 antibodies. The mean time to first antibody detection in oral fluid was 8-13 days post-symptom onset. A longer time to first detection of oral fluid anti-SARS-CoV-2 S antibodies (aHR 0.96, 95% CI 0.92-0.99, p=0.020) and BMI ≥ 25kg/m2 (aHR 0.37, 95% CI 0.18-0.78, p=0.009) were independently associated with a longer time to SARS-CoV-2 viral RNA clearance. Fever as one of first three COVID-19 symptoms correlated with shorter time to viral RNA clearance (aHR 2.06, 95% CI 1.02-4.18, p=0.044).Conclusions We demonstrate that delayed rise of oral fluid SARS-CoV-2-specific antibodies, elevated BMI, and absence of early fever are independently associated with delayed URT viral RNA clearance.Competing Interest StatementDr. Mehta received speaker fees from Gilead Sciences. No other conflicts.Clinical TrialNCT04496466Funding StatementThis work was supported by the Johns Hopkins University School of Medicine COVID-19 Research and Response Program Fund and the Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases Discovery Program. This research has been facilitated by the infrastructure and resources provided by the Johns Hopkins University Center for AIDS Research. The project described was supported by Grant Number 1P30AI094189 from the National Institute of Allergy And Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy And Infectious Diseases or the National Institute of Health. We thank the National Institute of Infectious Diseases, Japan, for providing VeroE6TMPRSS2 cells and acknowledge the Centers for Disease Control and Prevention, BEI Resources, NIAID, NIH for SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-5228. Salary support for AARA from NIH/NIAID (K08AI143391), YCM from NIH (U54EB007958-12, U5411090366, U54HL143541-02S2, UM1AI068613), JAT from NIH/NIAID (K23AI135102). AP was supported by the NIH/NIAID Center of Excellence in Influenza Research and Surveillance contract HHS N272201400007C. ALC & SLK were supported by NIH U54CA260492. Funding was also provided by the FIA Foundation, a gift from the GRACE Communications Foundation (CDH, NP, KK), NIAID grant R21AI139784 (CDH and NP), National Institute of Environmental Health Sciences (NIEHS) grant R01ES026973 (CDH, NP, KK), NIAID grant R01AI130066 and NIH grant U24OD023382 (CDH).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of the Johns Hopkins University School of Medicine.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data is not currently available, but can be made available upon request.